Clinical observation of combined treatment of antirotinib in HER-2 negative advanced breast cancer
Objective To observe the efficacy and safety of antirotinib combined therapy in human epidermal growth factor receptor-2(HER-2)negative advanced breast cancer.Methods Clinical medical records of patients with HER2-negative advanced breast cancer who received anrotinib combination therapy in Jiangsu Cancer Hospital from October 18,2019 to July 15,2023 were collected.RECIST 1.1 standard was used to evaluate the efficacy and CTCAE 5.0 standard was used to evaluate the adverse reactions.Survival curve was drawn by Kaplan-Meier method,and survival difference was tested by Log-rank.Results A total of 85 patients were included.The median follow-up time was 8.7 months(1.6-41.8 months),the median progression-free survival time(PFS)was 7.4 months(95%CI:6.5-9.0 months),and the ORR,DCR,and CBR were 37.6%,85.9%,and 52.9%,respectively.The median PFS for patients with hormone receptor-positive and triple-negative breast cancer were 6.8 months(95%CI:5.7 to 8.9 months)and 8.7 months(95%CI:7.0-11.7 months),respectively.There was no significant difference in median PFS between patients treated with≤3 lines and those treated with＞3 lines[7.6 months(95%CI:6.8-10.2 months)vs.6.7 months(95%CI:5.8-10.2 months),P=0.531].The most common adverse reactions included thrombocytopenia(40.0%),neutropenia(36.5%),leukopenia(36.5%),anemia(23.5%)and elevated alanine transferase(20.0%).Conclusion The combined treatment of anrotinib showed good efficacy and controllable adverse reactions in patients with HER-2 negative advanced breast cancer who failed standard treatment.
Metastatic breast cancerAnlotinibHER-2 negativeEfficacySide effects
NETL
NSTL
万方数据
